Literature DB >> 27324804

Visual versus automated analysis of [I-123]FP-CIT SPECT scans in parkinsonism.

Elina Mäkinen1,2,3, Juho Joutsa4,5,6, Jarkko Johansson6, Maija Mäki7, Marko Seppänen7, Valtteri Kaasinen4,5,6.   

Abstract

The clinical evaluation of dopamine transporter (DAT) SPECT scans typically relies on visual analysis in combination with an automated semi-quantitative method. The interpretation of the results may be difficult in cases that show disagreement between the two methods on the borderline of abnormality. The frequency and clinical characteristics of such cases are unclear. Automated semi-quantitative analyses and independent visual analyses by two experienced nuclear medicine physicians and four inexperienced raters were performed for 120 patients with clinically uncertain parkinsonism scanned with brain [I-123]FP-CIT SPECT. Agreement was evaluated with kappa statistics. The clinical characteristics of patients who had discrepant findings between the two analysis methods were investigated. The expert raters outperformed nonexperts in terms of agreement between visual and automated analyses (κ = 0.66, 0.72 vs. 0.23-0.54) and between raters (κ = 0.81 vs. 0.44-0.63). Twelve patients showed discrepant findings between the visual and automated analyses. These patients were older compared to other patients (p = 0.023), had 17.6 % lower mean striatal tracer binding compared to normal scans (p = 0.003) and 62.7 % higher compared to abnormal scans (p < 0.001). After a minimum of 4.5 years of clinical follow-up, none of these patients developed neurodegenerative parkinsonism. Clinical DAT SPECT scans show discrepancies between visual and automated analyses in 10 % of cases. The patients with discrepant findings are older, show normal to slightly abnormal tracer binding, and importantly, do not develop neurodegenerative parkinsonism syndromes. Visual analyses by experienced raters are reliable, but the diagnostic accuracy in discrepant cases can be improved by an automated method.

Entities:  

Keywords:  Analysis; Clinical; Dopamine transporter; Parkinsonism; SPECT

Mesh:

Substances:

Year:  2016        PMID: 27324804     DOI: 10.1007/s00702-016-1586-6

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  29 in total

Review 1.  Parkinson's disease: diagnosis.

Authors:  David J Brooks
Journal:  Parkinsonism Relat Disord       Date:  2012-01       Impact factor: 4.891

Review 2.  SPECT imaging evaluation in movement disorders: far beyond visual assessment.

Authors:  Kosmas Badiavas; Elisavet Molyvda; Ioannis Iakovou; Magdalini Tsolaki; Kyriakos Psarrakos; Nikolaos Karatzas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-02       Impact factor: 9.236

3.  SPECT study with I-123-Ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson's disease?

Authors:  G Gerasimou; D C Costa; E Papanastasiou; S Bostanjiopoulou; M Arnaoutoglou; E Moralidis; T Aggelopoulou; A Gotzamani-Psarrakou
Journal:  Ann Nucl Med       Date:  2012-03-03       Impact factor: 2.668

4.  Automated quantification with BRASS reduces equivocal reporting of DaTSCAN (123I-FP-CIT) SPECT studies.

Authors:  Deborah Ruth Pencharz; Paul Hanlon; Riddhika Chakravartty; Shaunak Navalkissoor; Ann-Marie Quigley; Thomas Wagner; Thomas Wagner
Journal:  Nucl Med Rev Cent East Eur       Date:  2014

5.  Dopamine transporter imaging in essential tremor with and without parkinsonian features.

Authors:  Olga Waln; Ying Wu; Reid Perlman; Juliet Wendt; Anh K Van; Joseph Jankovic
Journal:  J Neural Transm (Vienna)       Date:  2015-07-02       Impact factor: 3.575

6.  Effects of aging and gender on striatal and extrastriatal [123I]FP-CIT binding in Parkinson's disease.

Authors:  Valtteri Kaasinen; Juho Joutsa; Tommi Noponen; Jarkko Johansson; Marko Seppänen
Journal:  Neurobiol Aging       Date:  2015-01-22       Impact factor: 4.673

7.  Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study.

Authors:  Andreas R Kupsch; Nin Bajaj; Frederick Weiland; Antonio Tartaglione; Susanne Klutmann; Melanie Buitendyk; Paul Sherwin; Ann Tate; Igor D Grachev
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-04-06       Impact factor: 10.154

Review 8.  Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice.

Authors:  Fang Ba; W R Wayne Martin
Journal:  Parkinsonism Relat Disord       Date:  2014-11-20       Impact factor: 4.891

Review 9.  The relationship between essential tremor and Parkinson's disease.

Authors:  Mary Ann Thenganatt; Joseph Jankovic
Journal:  Parkinsonism Relat Disord       Date:  2015-10-09       Impact factor: 4.891

10.  The relationship between Parkinson's disease and essential tremor: review of clinical, epidemiologic, genetic, neuroimaging and neuropathological data, and data on the presence of cardinal signs of parkinsonism in essential tremor.

Authors:  Félix Javier Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-09-12
View more
  7 in total

Review 1.  Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes.

Authors:  Ralph Buchert; Carsten Buhmann; Ivayla Apostolova; Philipp T Meyer; Jürgen Gallinat
Journal:  Dtsch Arztebl Int       Date:  2019-11-01       Impact factor: 5.594

2.  Dopaminergic imaging separates normal pressure hydrocephalus from its mimics.

Authors:  Gilles Allali; Valentina Garibotto; Ismini C Mainta; Nicolas Nicastro; Frederic Assal
Journal:  J Neurol       Date:  2018-08-28       Impact factor: 4.849

3.  A new quantitative index in the diagnosis of Parkinson syndrome by dopamine transporter single-photon emission computed tomography.

Authors:  Ryota Bando; Hideki Otsuka; Tamaki Otani; Noritake Matsuda; Shota Azane; Yamato Kunikane; Yoichi Otomi; Wataru Sako; Yuishin Izumi; Masafumi Harada
Journal:  Ann Nucl Med       Date:  2021-02-25       Impact factor: 2.668

4.  Impact of the cerebrospinal fluid-mask algorithm on the diagnostic performance of 123I-Ioflupane SPECT: an investigation of parkinsonian syndromes.

Authors:  Yu Iwabuchi; Tadaki Nakahara; Masashi Kameyama; Yohji Matsusaka; Yasuhiro Minami; Daisuke Ito; Hajime Tabuchi; Yoshitake Yamada; Masahiro Jinzaki
Journal:  EJNMMI Res       Date:  2019-09-03       Impact factor: 3.138

5.  Brain SPECT as an Imaging Biomarker for Evaluating Effects of Novel Treatments in Psychiatry-A Case Series.

Authors:  Steven R D Best; Natalie Haustrup; Dan G Pavel
Journal:  Front Psychiatry       Date:  2022-01-13       Impact factor: 4.157

6.  A Novel Automatic Approach for Calculation of the Specific Binding Ratio in [I-123]FP-CIT SPECT.

Authors:  Mahmudur G M Rahman; Muhammad M Islam; Tetsuya Tsujikawa; Hidehiko Okazawa
Journal:  Diagnostics (Basel)       Date:  2020-05-09

7.  Individual parkinsonian motor signs and striatal dopamine transporter deficiency: a study with [I-123]FP-CIT SPECT.

Authors:  Elina Mäkinen; Juho Joutsa; Elina Jaakkola; Tommi Noponen; Jarkko Johansson; Miia Pitkonen; Reeta Levo; Tuomas Mertsalmi; Filip Scheperjans; Valtteri Kaasinen
Journal:  J Neurol       Date:  2019-01-28       Impact factor: 4.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.